Introduction {#Sec1}
============

Falls are a major public health problem that causes considerable morbidity and affects the quality of life of people around the world \[[@CR1]\]. Several risk factors for falls, such as age, physical inactivity, loss of balance, and loss of vision, have been identified. Due to both complications of their disease and a direct effect of the disease on bone quality, patients with type 2 diabetes are thought to have an increased fall and fracture risk \[[@CR2], [@CR3]\]. However, conflicting results about fall and fracture risk in patients with type 2 diabetes have been described. Compared to subjects with normal glucose metabolism, fall and fracture risk may be either comparable or increased in patients with type 2 diabetes \[[@CR3]--[@CR10]\]. These different results may be explained by differences in the way diabetes has been diagnosed (self-reported vs. an oral glucose tolerance test (OGTT)) and how falls and fractures have been reported (retrospective vs. prospective). Furthermore, indicators of diabetes severity such as the degree of glucose control, the duration of disease, and the prevalence of insulin use are often not reported. This may have resulted in study populations with different levels of exposure and, consequently, different results \[[@CR4], [@CR5], [@CR7], [@CR8], [@CR10]\].

Only few studies about fracture risk and no studies about fall risk in people with impaired glucose metabolism (defined as either impaired fasting glucose or impaired glucose tolerance) have been published. People with impaired glucose metabolism are often overweight, which is associated with a decreased fracture risk \[[@CR11]\], and have increased serum levels of insulin \[[@CR12]\], which stimulates bone formation. It may therefore be hypothesized that people with impaired glucose metabolism have a decreased fracture risk. Previous studies indeed showed a normal to decreased fracture risk in people with impaired glucose metabolism when compared to people with normal glucose metabolism \[[@CR6], [@CR12], [@CR13]\].

In the present study, we examined the association between glucose metabolism status and recent falls and previous fractures in a well-characterized cohort of participants from the Maastricht Study aged 50 years and older. Additionally, we examined the association between glucose control, insulin use, diabetes duration, and falls in the past 6 months and fractures at or above the age of 50. We hypothesized that the prevalence of falls and fractures in participants with impaired glucose metabolism is similar or decreased when compared to participants with normal glucose metabolism and that the prevalence of falls and fractures in participants with type 2 diabetes is increased only in those with inadequately regulated diabetes, insulin users and those with a long duration of the disease.

Methods {#Sec2}
=======

Study population and design {#Sec3}
---------------------------

We used data from the Maastricht Study, an observational prospective population-based cohort study. The rationale and methodology have been described previously \[[@CR14]\]. In brief, the study focuses on the etiology, pathophysiology, complications, and comorbidities of type 2 diabetes mellitus and is characterized by an extensive phenotyping approach. Eligible for participation were all home-dwelling individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known type 2 diabetes status, with an oversampling of individuals with type 2 diabetes for reasons of efficiency. The present report includes cross-sectional data from a subset of the first 3451 participants who completed the baseline survey between November 2010 and September 2013. Participants with type 1 diabetes mellitus or another type of diabetes (*n* = 41) were excluded. Participants aged under 50 (*n* = 457) were excluded because one of our main outcome measures is a historical fracture at or above the age of 50. From the remaining 2953 participants, data on falls in the past 6 months was available in 2688 participants and on fractures at or above the age of 50 in 2463 participants. To examine the association between type 2 diabetes and falls and fractures only in participants who already had diabetes at the date of their fall or fracture, we excluded participants with an unknown duration of diabetes (*n* = 243 for the fall analysis population and *n* = 209 for the fracture analysis population) and those with an unknown date of the fracture. For the fall analysis population, we further excluded participants with type 2 diabetes and a diabetes duration less than 1 year (*n* = 14), or missing data on covariates (*n* = 426), leaving 2005 participants for the fall analysis population. For the fracture analysis population, we further excluded type participants with type 2 diabetes who reported a fracture before being diagnosed with diabetes (*n* = 15), or missing data on covariates (*n* = 392), leaving 1847 participants for the fracture analysis population (Fig. [1](#Fig1){ref-type="fig"}). The examinations of each participant were performed within a time window of 3 months. All participants were ambulatory. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands, on the basis of the Health Council's opinion (Permit 131088-105234-PG). All participants gave written informed consent.Fig. 1Flow chart of patient selection

Measures {#Sec4}
--------

### Glucose metabolism status {#Sec5}

To determine glucose metabolism status, all participants, except those who used insulin, underwent a standardized 2-h 75 g OGTT after an overnight fast. For safety reasons, participants with a fasting glucose level \>11.0 mmol/L (\>200.0 mg/dl), as determined by a capillary blood glucose measurement, did not undergo the OGTT. Fasting glucose level, 2-h plasma glucose level, and information about diabetes medication were used to determine glucose metabolism status. Glucose metabolism was defined according to the WHO 2006 criteria into normal glucose metabolism (fasting plasma glucose \<6.1 mmol/L (\<110.0 mg/dl) and 2-h plasma glucose \<7.8 mmol/L (\<140.0 mg/dl) and no diabetes medication), impaired fasting glucose (fasting plasma glucose 6.1--6.9 mmol/L (110.0--125.0 mg/dl) and 2-h plasma glucose \<7.8 mmol/L (\<140.0 mg/dl) and no diabetes medication), impaired glucose tolerance (fasting plasma glucose \<7.0 mmol/L (\<126.0 mg/dl) and 2-h plasma glucose ≥7.8 and \<11.1 mmol/L (≥140.0 and \<200.0 mg/dl) and no diabetes medication), and type 2 diabetes (fasting plasma glucose ≥7.0 mmol/L (≥126.0 mg/dl) or 2-h plasma glucose ≥11.1 mmol/L (≥200.0 mg/dl) or diabetes medication) \[[@CR15]\]. Individuals without type 1 diabetes who used diabetes medication were classified as having type 2 diabetes. For this study, we defined having either impaired fasting glucose or impaired glucose tolerance as impaired glucose metabolism. Use of glucose-lowering medication was assessed during a medication interview where generic name, dose, and frequency were registered. Diabetes duration was assessed by questionnaire. HbA1c level was determined as described elsewhere \[[@CR14]\].

The group with type 2 diabetes was divided into subgroups of participants with well-regulated disease (HbA1c ≤7 % (≤53 mmol/mol)) and with inadequately regulated disease (HbA1c \>7 % (\>53 mmol/mol)), in insulin and non-insulin users; and in participants with a diabetes duration ≤5 years and \>5 years.

### Falls and fractures {#Sec6}

Using a web-based questionnaire, participants were asked if they experienced a fall in the past 6 months, and, if so, how many times they fell in the past 6 months. Participants who fell two or more times in the past 6 months were labeled as recurrent fallers. Additionally, participants were asked if they had ever had a fracture and, if so, which bone(s) and the date(s) of the fracture(s). A fall in the past 6 months and a fracture at or above the age of 50 were our primary end points.

### Covariates {#Sec7}

The following covariates were included: age, sex, educational level, BMI, moderate-to-vigorous physical activity (MVPA), history of cardiovascular disease (CVD), smoking status, alcohol use, use of blood pressure lowering medication, use of lipid-modifying medication, use of benzodiazepines, depression, and cognitive performance.

Level of education was assessed by questionnaire and classified into three categories: low (no education; primary education; or lower vocational education), intermediate (intermediate general secondary education; intermediate vocational education; or higher general secondary education), and high (higher vocational education; or university).

Weight and height were measured without shoes and wearing light clothing using a scale and stadiometer to the nearest 0.5 kg or 0.1 cm (Seca, Hamburg, Germany). BMI was calculated by dividing the weight in kilogram by the height in centimeters squared.

MVPA, in hours per week, was calculated from the modified Community Health Activities Model Program for Seniors (CHAMPS) questionnaire \[[@CR16]\]. Activities accounted as MVPA were fast walking, fast cycling, heavy gardening, heavy household work, jogging/running, swimming, tennis, team sport, and intensive exercise.

History of CVD, smoking behavior, and alcohol consumption were assessed by questionnaire. Participants were regarded as having a history of CVD if they reported to have had a myocardial infarction and/or cerebrovascular infarction or hemorrhage, and/or percutaneous artery angioplasty or vascular surgery on the coronary, abdominal, peripheral or carotid arteries. Smoking behavior was classified as never, former, and current.

Alcohol consumption was classified into three categories: non-consumers, low consumers (≤7 glasses per week for women and ≤14 glasses per week for men), and high consumers (\>7 glasses per week for women and \>14 glasses per week for men).

Use of blood pressure lowering medication, lipid-modifying medication, and sleep medication was assessed during a medication interview where generic name, dose, and frequency were registered.

Presence of a depressive disorder in the preceding 2 weeks was assessed by the Mini International Neuropsychiatric Interview according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), as described in detail elsewhere \[[@CR17]\].

General cognitive performance was assessed using the Minimal Mental State Examination (MMSE) \[[@CR18]\]. The examination resulted in a score between 0 and 30, with a score of 24 or less being labeled as impaired cognitive function.

### Statistical analysis {#Sec8}

All statistical analyses were performed using the Statistical Package for Social Sciences (version 22.0; IBM, Chicago, IL, USA). General characteristics of the study population were compared between the group with normal glucose metabolism, the group with impaired glucose metabolism, and the group with type 2 diabetes. One-way ANOVA was used to test for significant differences of continuous variables and a chi-square test for differences in categorical variables between the normal glucose metabolism, the impaired glucose metabolism, and the type 2 diabetes groups. To examine the association between glucose metabolism status and falls or fractures, and to examine the association between diabetes regulation, insulin use, or duration of diabetes and falls or fractures, logistic regression analysis was used, yielding odds ratios (OR) and 95 % confidence intervals (CI). The same models were used for all regression analyses; model 1 was an unadjusted model; model 2 included age, sex, and level of education; and model 3 was additionally adjusted for BMI, MVPA, a history of CVD, smoking status, alcohol consumption, the use of blood pressure lowering medication, the use of lipid-modifying drugs, the use of sleep medication, depression, and cognitive function. A *p* value less than 0.05 was considered statistically significant. In additional analyses, the association between glucose metabolism status and recurrent falls was examined, using multinomial logistic regression analysis. Interactions of sex of the participant with the respective exposure variables of interest (i.e., glucose metabolism status, diabetes regulation, insulin use, or duration of diabetes) were tested for all regression analyses.

Results {#Sec9}
=======

General characteristics of the fall analysis population according to glucose metabolism status are shown in Table [1](#Tab1){ref-type="table"}. In total, 1246 participants were classified as having normal glucose metabolism, 359 as having impaired glucose metabolism, and 400 as having type 2 diabetes. Participants with type 2 diabetes were the oldest, the least likely to be female, had the lowest level of education, the highest BMI, and the highest prevalence of depression. Participants with normal glucose metabolism had the lowest prevalence of CVD and the highest prevalence of non-smokers. Alcohol consumption was the lowest in the group with type 2 diabetes. The mean HbA1c level of the group with type 2 diabetes was 7.0 % (53.4 mmol/mol); almost 93 % used antidiabetic drugs, including insulin in 26 %. The median diabetes duration was 7.0 years. The prevalence of a fall in the past 6 months and the number of falls in the past 6 months was not significantly different between the groups, while the prevalence of a fracture at or above the age of 50 was lowest in the group with type 2 diabetes. The general characteristics of the fracture analysis population according to glucose metabolism status were comparable to those of the fall analysis population (not tabulated).Table 1General characteristics of the study population by glucose metabolism statusNGM (*n* = 1246)IGM (*n* = 359)T2DM (*n* = 400)*p* valueAge (years)60.5 (6.1)63.0 (5.9)63.4 (6.3)\<0.001Female sex708 (56.8)158 (44.0)128 (32.0)\<0.001Level of education - Low344 (27.6)131 (36.5)165 (41.3)\<0.001 - Medium324 (26.0)92 (25.6)124 (31.0) - High578 (46.4)136 (37.9)111 (27.8)BMI (kg/m^2^)25.5 (3.6)27.9 (4.2)29.7 (4.7)\<0.001Self-reported MVPA (hours/week)6.2 (4.5)5.2 (4.2)4.4 (4.1)\<0.001History of CVD154 (12.4)50 (13.9)120 (30.0)\<0.001Smoking status - Never471 (37.8)103 (28.7)109 (27.3)\<0.001 - Former645 (51.8)219 (61.0)241 (60.3) - Current130 (10.4)37 (10.3)50 (12.5)Alcohol consumption category - None142 (11.4)52 (14.5)114 (28.5)\<0.001 - Low715 (57.4)194 (54.0)217 (54.3) - High389 (31.2)113 (31.5)69 (17.3)Medication use - Antidiabetic drugs----371 (92.8)-- - Insulin----104 (26.0)-- - Blood pressure lowering drugs303 (24.3)168 (46.8)296 (74.0)\<0.001 - Lipid-modifying drugs237 (19.0)135 (37.6)315 (78.8)\<0.001 - Sleep medication27 (2.2)11 (3.1)9 (2.3)0.61Depression21 (1.7)9 (2.5)20 (5.0)0.001MMSE score29.2 (1.1)28.9 (1.2)28.7 (1.4)\<0.001HbA1c (%)5.5 (0.3)5.7 (0.4)7.0 (1.1)\<0.001HbA1c (mmol/mol)36.4 (3.7)39.0 (4.4)53.4 (11.5)\<0.001Duration of diabetes in years, mean (IQR)----7.0 (9.0)--Fall in the past 6 months204 (16.4)72 (20.1)66 (16.5)0.25Number of falls in the past 6 months - 01042 (83.6)287 (79.9)334 (83.5)0.44 - 1134 (10.8)51 (14.2)42 (10.5) - ≥270 (5.6)21 (5.8)24 (6.0)Fracture ≥50 years of age119 (10.3)40 (12.3)19 (5.4)0.006Continues variables are presented as mean (SD) unless otherwise stated, categorical variables as number of participants (%)*BMI* body mass index, *CVD* cardiovascular disease, *IGM* impaired glucose metabolism, *IQR*Interquartile range *MVPA* moderate-to-vigorous physical activity, *NGM* normal glucose metabolism, *SD* standard deviation, *T2DM* type 2 diabetes

Table [2](#Tab2){ref-type="table"} shows the association between glucose metabolism status and falls or fractures. The odds ratio (OR) for a fall was significantly increased in participants with impaired glucose metabolism (OR (95 % CI) 1.37 (1.01--1.87)) after adjustment for age, sex, and level of education (model 2). After further adjustment (model 3) the OR was no longer statistically significant (OR (95 % CI) 1.28 (0.93--1.77)). The addition of BMI to model 2 resulted in loss of statistical significance (data not shown). When the impaired glucose metabolism group was divided into participants with impaired fasting glucose and in participants with impaired glucose tolerance, the odds for a fall was increased only in participants with impaired glucose tolerance after adjustment for age, sex, and level of education (model 2, OR (95 % CI) 1.42 (1.01--1.99)). The odds for a fall in the group with type 2 diabetes was not statistically significantly different from those with a normal glucose metabolism in all models.Table 2The association between glucose metabolism status and falls in the past 6 months or fractures at or above the age of 50Number of falls/fracturesNumber of participantsModel 1\
OR (95 % CI)Model 2\
OR (95 % CI)Model 3\
OR (95 % CI)*Falls*NGM2041246RefRefRefIGM723591.28 (0.95--1.73)*1.37 (1.01--1.87)*1.28 (0.93--1.77) - IFG16931.06 (0.61--1.86)1.25 (0.71--2.20)1.16 (0.65--2.07) - IGT562661.36 (0.98--1.90)*1.42 (1.01--1.99)*1.32 (0.93--1.89)T2DM664001.01 (0.75--1.37)1.17 (0.85--1.62)0.95 (0.64--1.40)*Fractures*NGM1191162RefRefRefIGM403261.23 (0.84--1.80)1.20 (0.80--1.78)1.28 (0.84--1.95) - IFG9851.04 (0.51--2.13)1.24 (0.59--2.58)1.30 (0.62--2.76) - IGT312411.29 (0.85--1.97)1.19 (0.76--1.85)1.28 (0.81--2.02)T2DM19359*0.49 (0.30--0.81)0.55 (0.32--0.92)*0.70 (0.38--1.27)Model 1: unadjusted, model 2: adjusted for age, sex, and level of education, model 3: model 2 + BMI, MVPA, a history of CVD, smoking status, alcohol consumption, the use of blood pressure lowering drugs, the use of lipid-modifying drugs, the use of sleep medication, depression, and cognitive function. NGM is the reference category*CI* confidence interval, *IGM* impaired glucose metabolism, *NGM* normal glucose metabolism, *OR* odds ratio, *T2DM* type 2 diabetes mellitusStatistically significant results are presented in italic

The odds for a fracture in the group with impaired glucose metabolism were not statistically significantly different from those with a normal glucose metabolism in all models. The odds for a fracture were significantly decreased in participants with type 2 diabetes after adjustment for age, sex, and level of education (model 2, OR (95 % CI) 0.55 (0.32--0.92)), when compared to participants with normal glucose metabolism. The association was not significantly different anymore after further adjustment for BMI, MVPA, a history of CVD, smoking status, alcohol consumption, the use of blood pressure lowering drugs, lipid-modifying drugs, and sleep medication, and depression and cognitive function (model 3, OR (95 % CI) 0.70 (0.38--1.27)).

Table [3](#Tab3){ref-type="table"} shows the association between diabetes regulation, insulin use, or diabetes duration and falls or fractures in the group with type 2 diabetes. The mean HbA1c level of the subgroup with an HbA1c \>7 % (\>53 mmol/mol) was 8.0 ± 1.0 % (64.4 ± 11.4 mmol/mol); the mean HbA1c level of the subgroup with an HbA1c ≤7 % (≤53 mmol/mol) was 6.4 ± 0.4 % (46.9 ± 4.3 mmol/mol). The median duration of diabetes of the subgroup with a diabetes duration \>5 years was 11.0 (interquartile range (IQR) 8.0) years, and of the subgroup with a diabetes duration ≤5 years was 3.0 (IQR 2.0) years. The OR for a fall of participants with an HbA1c \>7 % (53 mmol/mol), insulin users, or participants with a diabetes duration of more than 5 years was not statistically significantly different from those of participants with an HbA1c ≤7 % (53 mmol/mol), non-insulin users, and those with a duration of 5 years or less, respectively, in all the models. Similarly, there were no statistically significant associations between HbA1c, insulin use, or diabetes duration and fractures.Table 3The association between diabetes regulation, insulin use, or duration of diabetes and falls or fracturesNumber of falls/fracturesNumber of participantsModel 1\
OR (95 % CI)Model 2\
OR (95 % CI)Model 3\
OR (95 % CI)*Falls* HbA1c ≤7 % (53 mmol/mol)41250RefRefRef HbA1c \>7 % (53 mmol/mol)251501.02\
(0.59--1.76)1.09\
(0.62--1.92)1.05\
(0.58--1.90) Insulin −44296RefRefRef Insulin +221041.54\
(0.87--2.72)1.63\
(0.90--2.94)1.51\
(0.79--2.89) Diabetes duration ≤5 years30173RefRefRef Diabetes duration \>5 years362270.90\
(0.53--1.53)0.86\
(0.50--1.49)0.83\
(0.46--1.47)*Fractures* HbA1c ≤7 % (53 mmol/mol)13225RefRefRef HbA1c \>7 % (53 mmol/mol)61340.76\
(0.28--2.06)0.69\
(0.25--1.90)0.53\
(0.18--1.59) Insulin −13269RefRefRef Insulin +6901.41\
(0.52--3.82)1.27\
(0.46--3.50)1.39\
(0.44--4.33) Duration of diabetes ≤5 years11158RefRefRef Duration of diabetes \>5 years82010.55\
(0.22--1.41)0.50\
(0.19--1.31)0.52\
(0.19--1.44)Model 1: unadjusted, model 2: adjusted for age, sex, and level of education, model 3: model 2 + BMI, MVPA, a history of CVD, smoking status, alcohol consumption, the use of blood pressure lowering drugs, the use of lipid-modifying drugs, the use of sleep medication, depression, and cognitive function. HbA1c ≤7 % (53 mmol/mol), insulin, and duration of diabetes ≤5 years are the reference categories*CI* confidence interval, *OR* odds ratio

In additional analyses, we examined the association between glucose metabolism status and recurrent falls (data not tabulated). Impaired glucose metabolism and type 2 diabetes were not statistically significantly associated with recurrent falls. Finally, the results of the regression analyses for a fall in the past 6 months or recurrent falls in the past 6 months were similar to those described above, when the fracture analysis population instead of the fall analysis population was used.

Discussion {#Sec10}
==========

In this study, we examined the association between glucose metabolism status and a history of fractures and recent falls in a group of 2005 participants at or above the age of 50 from the Maastricht Study. In contrast to our hypothesis, we did not find a significant association between glucose metabolism status and a history of falls or fractures. Diabetes severity, in terms of inadequately regulated disease, insulin use, or duration of diabetes, was also not significantly associated with increased odds of prior fractures or recent falls.

Previous cross-sectional fall studies showed no significant difference in fall rate between participants with and without type 2 diabetes \[[@CR9], [@CR19]\]. However, both studies used a small sample size and only showed results of univariate analyses. The results of previous prospective studies on fall risk in patients with type 2 diabetes are conflicting; some studies showed an increased fall risk \[[@CR8], [@CR10], [@CR20], [@CR21]\], while others showed a fall risk similar to participants without diabetes \[[@CR7], [@CR13]\].

Our study is in line with two out of three previous cross-sectional studies that investigated the association between type 2 diabetes and fractures, where significant association between type 2 diabetes and all types of fractures and hip fractures specifically was showed \[[@CR4], [@CR6]\]. Additionally, no association between an impaired fasting glucose and fractures was shown \[[@CR6]\]. In contrast, two meta-analyses and a recent large prospective study showed an increased fracture risk in patients with type 2 diabetes \[[@CR3], [@CR22], [@CR23]\]. However, none of the prospective fall and fracture studies provided information on HbA1c levels, the percentage of insulin users, and the duration of diabetes. This lack of information hampers the comparison of these studies, since they may have been conducted in patient populations with different characteristics regarding type 2 diabetes.

In our study, participants with type 2 diabetes had generally well-regulated diabetes (mean HbA1c level 7.0 % (53.4 mmol/mol)), a relatively short median duration of the disease (7.0 years), and the percentage of insulin users was low (26.0 %). A potential explanation for the non-significant differences in fall and fracture rate between those with and without type 2 diabetes is that an increased fall and fracture risk is only present in patients with more severe and longer duration of the disease. Indeed, several prospective cohort studies showed that only inadequately regulated diabetes was associated with an increased fall and fracture risk \[[@CR13], [@CR24], [@CR25]\]. In the current, study we did not find statistically significant differences in the odds of falls and fractures in inadequately versus adequately regulated participants with type 2 diabetes, in those with a duration of diabetes \>5 years versus ≤5 years, nor between insulin users versus non-insulin users. The cut-off values for HbA1c level and duration of diabetes we chose can be discussed. We used an HbA1c level of 7 % (53 mmol/mol) as cut-off value because this is the target value for diabetes treatment \[[@CR26]\]. The mean HbA1c level of our inadequately regulated group was 8.0 % (64.4 mmol/mol), which is close to the target value and may explain the absence of the different fall and fracture rates between the group with adequately and inadequately regulated diabetes. Only few patients in our cohort of patients with type 2 diabetes had HbA1c levels above 9 %; it was therefore not possible to examine the association between different degrees of glucose metabolism regulation and falls or fractures.

The absolute number of fractures in both of our groups of participants with an impaired glucose metabolism and of participants with type 2 diabetes was very low (*n* = 40 and *n* = 19, respectively), which is remarkable given the large number of participants in each group and the fact that quite a high number of participants reported at least one fall in the previous 6 months (*N* = 66 and *N* = 56, respectively). Due to this low absolute number of total fractures, there may be a power problem for showing an association between glucose metabolism status and fractures.

The meta-analysis by Janghorbani et al. showed an increased hip fracture risk, but no association between type 2 diabetes and fractures of the distal forearm, proximal humerus, or vertebra \[[@CR22]\]. In contrast, the meta-analysis by Vestergaard et al. showed an increase in wrist fracture risk, but not in non-vertebral and spine fracture risk \[[@CR3]\]. Because of the low absolute number of fractures observed in our study, we were not able to examine specific types of fractures.

To the best of our knowledge, up to this date, no studies have been performed on the association between impaired glucose metabolism and falls. Fracture risk has previously been shown to be normal or decreased in participants with impaired glucose metabolism \[[@CR6], [@CR12], [@CR13]\]. Because most fractures occur due to a fall \[[@CR27]\], a normal to decreased fall risk may be expected. On the other hand, our participants with impaired glucose metabolism were less physically active than participants with normal glucose metabolism and this may lead to some degree of muscle weakness in participants with impaired glucose metabolism and therefore an increased fall risk. Furthermore, the BMI of our participants with impaired glucose metabolism was significantly higher than the BMI of participants with normal glucose metabolism, which could also contribute to an increased falling frequency \[[@CR28]\]. In our study, we found a significant association between impaired glucose metabolism and a fall in the past 6 months after adjustment for demographic factors. The association became non-significant after adjustment for BMI and other confounders, so the increased odds of fall in participants with an impaired glucose metabolism in model 2 may be partly explained by their increased BMI. No statistically significant association between participants with impaired glucose metabolism and fractures was found.

Strengths of this study include the objective determination of the glucose metabolism status in a large study population, the well-characterized study cohort, and the availability of extensive information about our participants with type 2 diabetes. In contrast to many previous studies, glucose metabolism status was determined with an OGTT, which allowed us to compare distinct groups of participants. Information about insulin use, an objectively determined HbA1c level, and the duration of diabetes was well registered for all participants with type 2 diabetes which enabled us to compare different subgroups of participants with type 2 diabetes.

Limitations of our study include the absence of a definition of 'fall' in our questionnaire, the cross-sectional study design, the use of retrospectively collected and self-reported data on falls and fractures, and the lack of information about complications of diabetes. According to the PROFANE guideline \[[@CR29]\], a fall should be defined as "an unexpected event in which the participants come to rest on the ground, floor, or lower level." Due to the absence of this definition, participants may have either reported a fall that did not meet the definition or not reported a fall that did meet the definition. Prospective collection of data on falls using a fall diary and on fractures using radiology rapports is preferable over the use of self-reported falls and fractures. However, previous research showed that the accuracy of both self-reported falls and fractures is reasonable \[[@CR30]--[@CR32]\]. Because data about falls and fractures were collected retrospectively, it is not possible to assess whether participants labeled as having impaired glucose metabolism already had impaired glucose metabolism at the moment of their fall or fracture. Because we wanted to be sure to examine the association between type 2 diabetes and falls and fractures only in participants who already had diabetes at the date of their fall or fracture, we excluded participants with an unknown duration of diabetes and those with an unknown date of the fracture. This may have contributed to the low absolute number of fractures that were left for our analyses. In our study, we used HbA1c level, insulin use, and diabetes duration instead of complications of diabetes as markers of diabetes severity. Future studies are needed to study the association between complications of diabetes and falls and fractures.

In conclusion, glucose metabolism status was not significantly associated with a history of fractures or recent falls. Furthermore, diabetes severity was also not significantly associated with prior fractures or recent falls. This study suggests that the fall and fracture rate may not be increased in relatively young patients with generally well-regulated type 2 diabetes. Prospective cohort studies with an extensively described type 2 diabetes cohort should be performed to confirm these results.
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